EMIT Imaging specializes in Cryo-Fluorescence Tomography (CFT), a cutting-edge 3D imaging technology that enhances the visualization of drug distribution and protein expression in whole animals. Their flagship platform, Xerra™, is designed to provide high-resolution and high-sensitivity imaging, making it a valuable tool for drug discovery and delivery, oncology, immunotherapy, gene and cell therapy, and neuroscience. CFT allows researchers to monitor biodistribution, expression, and biochemical processes more effectively than traditional 2D in vivo fluorescence imaging techniques. By bridging the gap between cellular microscopy and larger-scale imaging methods like MRI and PET, CFT offers a comprehensive view of disease and treatment dynamics.

The CFT process involves a meticulous workflow that includes cryo-preserving samples, acquiring high-resolution images, and generating 3D image stacks for detailed analysis. EMIT Imaging also provides fee-for-service research at their state-of-the-art laboratories, allowing clients to send samples for expert handling and analysis. This technology is particularly beneficial for studying tumor models, understanding pharmacokinetics and pharmacodynamics, and visualizing gene expression in various biological contexts. Overall, EMIT Imaging's innovative approach significantly advances preclinical imaging capabilities, facilitating deeper insights into biological and therapeutic processes.

United States

EMIT Imaging is the leading manufacturer of CFT systems and provider of CFT fee-for-service research for the global life sciences market. CFT was created to better visualize drug distribution and protein expression (pharmacokinetics/PK, and pharmacodynamics/PD) in whole animals at high resolution and sensitivity. CFT applications span drug discovery and delivery, oncology and immunotherapy, gene and cell therapy, neuroscience, and beyond. The company is based in Baltimore, MD, and Boston, MA.

EMIT Imaging

Company Details